You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

53 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2024 - 2025

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "53 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/nce-1/.
Media collateral
These NCE-1 dates indicate the first opportunity for generic drug companies to file Abbreviated New Drug Applications (ANDAs) for generic entry into branded drug markets. Generic launch is dependent on many factors, including FDA approval and patents. This information is provided as a rough estimate of generic application, and does not indicate when generics will launch. For more information see the complete DrugPatentWatch database.
When can drug patent challenges be filed against GALLIUM GA 68 GOZETOTIDE?

Generic name: gallium ga-68 gozetotide
NCE-1 Date: December 2024

GALLIUM GA 68 GOZETOTIDE is a drug marketed by Univ Ca Los Angeles and Univ Of Ca San Fran

This drug has ninety-three patent family members in twenty-one countries.

The generic ingredient in GALLIUM GA 68 GOZETOTIDE is gallium ga-68 gozetotide. There are sixteen drug master file entries for this API. Additional details are available on the gallium ga-68 gozetotide profile page.

When can drug patent challenges be filed against MYFEMBREE?

Generic name: estradiol; norethindrone acetate; relugolix
NCE-1 Date: December 2024

Drug Price Trends for MYFEMBREE
MYFEMBREE is a drug marketed by Myovant Sciences. There are six patents protecting this drug.

This drug has one hundred and thirty-one patent family members in thirty-four countries.

See drug price trends for MYFEMBREE.

The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix. There are seventy-five drug master file entries for this API. Additional details are available on the estradiol; norethindrone acetate; relugolix profile page.

When can drug patent challenges be filed against CABENUVA KIT?

Generic name: cabotegravir; rilpivirine
NCE-1 Date: January 2025

CABENUVA KIT is a drug marketed by Viiv Hlthcare. There are six patents protecting this drug.

This drug has three hundred and ninety patent family members in fifty-one countries. There has been litigation on patents covering CABENUVA KIT

The generic ingredient in CABENUVA KIT is cabotegravir; rilpivirine. Additional details are available on the cabotegravir; rilpivirine profile page.

When can drug patent challenges be filed against PEPAXTO?

Generic name: melphalan flufenamide hydrochloride
NCE-1 Date: February 2025

PEPAXTO is a drug marketed by Oncopeptides Ab. There are six patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-one countries.

The generic ingredient in PEPAXTO is melphalan flufenamide hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the melphalan flufenamide hydrochloride profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.